Physician profile
Sunil Rajan
NPI 1407991177
$2,606.87
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $538 · 2021: $651 · 2022: $416 · 2023: $15.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,024.27 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $498.99 | 2019-2022 | |
| Mylan Specialty L.P. | $178.03 | 2019-2022 | |
| Grifols USA, LLC | $155.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.09 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $123.39 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $91.28 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $78.48 | 2019 | |
| Philips North America LLC | $48.22 | 2019 | |
| Genzyme Corporation | $40.91 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $38.66 | 2022 | |
| Genentech USA, INC. | $37.52 | 2019-2020 | |
| Insmed, INC. | $33.56 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $26.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.11 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.55 | 2022 | |
| Circassia INC. | $16.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.70 | 2019 | |
| Electromed, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.